MariTide (maridebart cafraglutide)_Dosage, benefits & legal status
Also known as maridebart cafraglutide, AMG 133, MariTide
An experimental once-a-month obesity shot.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is MariTide (maridebart cafraglutide)?
Plain language first. The technical label stays, but it never stands alone.Overview
It combines appetite signals in one long-lasting molecule you inject only once a month. It is still experimental.
MariTide is an unusual design, an antibody linked to two GLP-1 peptides that also blocks the GIP receptor.
What it's used for
An experimental once-a-month obesity shot, offering strong early weight loss with the convenience of monthly dosing.
How does MariTide (maridebart cafraglutide) work?
What it does in the body, and where.MariTide is structurally unlike anything else here: an antibody with two GLP-1 peptides attached, which blocks one receptor while activating another.
- 01It activates GLP-1The peptide halves do the familiar appetite work.
- 02It blocks GIP rather than activating itThis is the strange part. Tirzepatide activates GIP; this blocks it, and both approaches produce weight loss. The reason is genuinely not settled.
- 03The antibody body makes it last weeksAntibodies clear slowly, which is what allows monthly rather than weekly injection.
- 04Still investigationalPhase 2 is complete, phase 3 is running.
Hits 2 receptors at once.
What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- Weight loss with once-a-month dosingInvestigational
- Type 2 diabetesInvestigational
The published record
53
Records indexed for MariTide (maridebart cafraglutide)
41 in humans, 5 of them original studies.
27 registered trials, 2 with posted results.
Counted from Europe PMC indexing, not read by a person. Human means indexed under humans, which includes reviews and work on human cells. Original studies exclude reviews and lab work on human cells.Last updated 12 September 2026.
At a glance
Four things to know about MariTide (maridebart cafraglutide)
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
About 21 days
How much, and do you cycle it?
The range, and whether you take breaks.140 up to 420 mg per month (trial doses), monthly. Not cycled in the trialsTrial dose
Given continuously for the whole study period: MARITIME-1, 72 weeks. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break.
How long does it stay in the body?
The half-life, and where the figure comes from.About 21 daysTrial protocol
A peptide joined to an antibody, which is what makes monthly dosing possible.
Source: Jastreboff AM, et al. NEJM 2025, PMID 40549887, MARITIME-1
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
Your draw
2800 / 100 unitsHow do you store it?
Before mixing, and after.Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.
Unmixed lyophilized MariTide (maridebart cafraglutide) keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.
What are the side effects and cautions?
Known cautions and warnings for this compound.This compound is in clinical trials and is not sold in a standard vial, so there is no common vial size to show. Trial doses are given as prepared by the study, and the reconstitution calculator does not apply. Doses up to 420 mg a month are more than forty times the 10 mg reference vial.
Who should avoid it
- No formal contraindications established
- Pregnancy
Stop and get help
- Vomiting or dry-heaving that will not stop, especially with signs of dehydration
- Signs of an allergic reaction such as face or throat swelling, hives, or trouble breathing
Common effects
- Almost everyone in the trial had a stomach effect: nausea, vomiting, constipation, retching, or diarrhea
- Up to 27% stopped because of it, though slower dose increases cut that to about 8%
- No effect on bone density was found
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is MariTide (maridebart cafraglutide) approved?
And where the numbers on this page come from.No. MariTide (maridebart cafraglutide) is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin (subcutaneous)
- CheckedSeptember 2026
What has happened recently
We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.
You can compare this against the whole library, or read how to check a seller.
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sources
- Reviewed8 September 2026
What else is like MariTide (maridebart cafraglutide)?
Others in GLP-1 agonists, side by side.If you're weighing MariTide (maridebart cafraglutide), it's worth reading CT-388, Pemvidutide, and Zovaglutide (ZT-002) in the same class.
An experimental once-a-month obesity shot.
- Dose
- 140 up to 420 mg per month (trial doses)
- How often
- Monthly
An experimental weekly weight-loss shot in the tirzepatide family.
- Dose
- 4 up to 24 mg per week (trial doses)
- How often
- Weekly
An experimental weekly shot for weight loss and fatty liver.
- Dose
- 1.2 up to 2.4 mg per week (trial doses)
- How often
- Weekly
An experimental once-a-month weight-loss shot.
- Dose
- 80 up to 160 mg per month (trial doses)
- How often
- Monthly
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- Why Does My Peptide Injection Itch or Welt
Injection-site irritation, a histamine reaction, or a true allergy, and how to tell them apart.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
Sources
- Jastreboff et al., once-monthly maridebart cafraglutide for the treatment of obesity, a phase 2 trial(2025)Obesity cohort of 465 participants. Mean weight change at 52 weeks on the treatment policy estimand ranged from -12.3 percent upward across dose arms. In the separate obesity-diabetes cohort of 127 participants the range started at -8.4 percent, notably weaker.
- Phase 2 results for once-monthly maridebart cafraglutide presented at ADA(2025)Dosing was 140 mg, 280 mg or 420 mg every four weeks against placebo, with weight change at one year as the primary endpoint. Placebo was -2.5 percent. The trial reported no weight plateau at 52 weeks.
Last reviewed 8 September 2026
Beyond these, 53 records are indexed. Browse the records